Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress

Baxter International (BAX) shares surged after the company announced better-than-expected Q2 financial results and raised its fiscal 2026 guidance. The hospital product maker reported adjusted earnings of 54 cents per share and sales of $2.96 billion, exceeding analyst consensus. This positive performance was primarily driven by strong growth in Medical Products & Therapies and Healthcare Systems & Technologies segments.